Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 30 days later Oct 31, 2026 → Nov 30, 2026
See other at-risk trials from University of Miami

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Oct 31, 2026 to Nov 30, 2026
    • Study completion pushed from Nov 1, 2026 to Jul 1, 2027
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Eligibility criteria expanded, about 60 words
    • Collaborator revised
    v18
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 1, 2025 to Feb 4, 2025
    • Site details revised at 3 of 3 sites
    v17
  4. Primary completion date: Nov 1, 2025 to Oct 31, 2026
    • Study completion date: Nov 1, 2025 to Nov 1, 2026
    • Start date: Feb 1, 2025 to Mar 1, 2025
    v16
  5. Start date: Dec 1, 2024 to Feb 1, 2025v15
Show 13 earlier versionsHide 13 earlier versions
  1. Start date: Nov 1, 2024 to Dec 1, 2024v14
  2. Re-verified, no change to tracked fieldsv13
  3. Start date: Oct 1, 2024 to Nov 1, 2024v12
  4. Start date: Aug 31, 2024 to Oct 1, 2024v11
  5. Start date: Jul 1, 2024 to Aug 31, 2024v10
  6. Start date: Jun 1, 2024 to Jul 1, 2024v9
  7. Start date: Apr 1, 2024 to Jun 1, 2024v8
  8. Start date: Feb 1, 2024 to Apr 1, 2024v7
  9. Start date: Nov 1, 2023 to Feb 1, 2024v6
  10. Start date: Sep 1, 2023 to Nov 1, 2023v5
  11. Start date: Aug 1, 2023 to Sep 1, 2023v4
  12. Start date: Jun 1, 2023 to Aug 1, 2023v3
  13. Start date: May 1, 2023 to Jun 1, 2023v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.
Trial Details
NCT Number NCT05745285
Lead Sponsor University of Miami
Collaborators: Blood Cancer United
Conditions
(from sponsor)		 Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Related terms Hematologic Neoplasms, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Plasma Cell
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov